Breaking Down Daan Gene Co., Ltd. Financial Health: Key Insights for Investors

Investors diving into Daan Gene Co., Ltd. (002030.SZ) will find a company with mixed signals: quarterly revenue slid to CNY 164.93 million (a -13.50% year‑over‑year drop) and TTM revenue at CNY 765.48 million (down 17.66% year‑over‑year), while 2024 revenue fell to CNY 853.02 million (a 27.76% decline) as Biological Products still account for 96.20% of sales but reagent volumes plunged over 80% and gross margins contracted by 13.5 percentage points; profitability remains strained with a first‑half 2025 net loss of CNY 182.16 million (improved from a H1 2024 loss of CNY 399.22 million) amid ten consecutive quarters of net losses and a 2024 net loss of CNY 925.17 million, while liquidity and balance sheet metrics present buffers - total assets of CNY 9.12 billion, cash and short‑term investments of CNY 1.30 billion and a net cash position of CNY 759.67 million (CNY 0.54/share) versus total liabilities of CNY 1.16 billion - even as valuation shows a premium P/S of 11.22, P/B of 1.12 and a market cap of CNY 8.59 billion, with EBITDA, operating cash flow and free cash flow showing steep year‑over‑year declines and the company highlighting IVD innovation and mid‑to‑high‑end diagnostic expansion as its primary growth avenues.

Daan Gene Co., Ltd. (002030.SZ) - Revenue Analysis

• Quarter ending Sep 30, 2025: revenue CNY 164.93 million (-13.50% YoY).
• Trailing twelve months (TTM): revenue CNY 765.48 million (-17.66% YoY).
• Full-year 2024: revenue CNY 853.02 million (-27.76% vs prior year).
• Primary revenue source: Biological Products - 96.20% of total revenue.
• Reagent products: sales and production volumes down >80% YoY; gross margins down 13.50 percentage points.
• Management cites industry demand shifts and pricing adjustments as drivers of the decline.

• Revenue concentration risk is high given Biological Products' ~96% contribution.
• Large volume and margin hits in reagent products materially weaken top-line and profitability.
• Near-term recovery will depend on demand stabilization, pricing improvements, and any product mix shift away from heavily impacted reagent lines.

Daan Gene Co., Ltd. (002030.SZ) - Profitability Metrics

• Net loss (H1 2025): CNY 182.16 million (improved from CNY 399.22 million in H1 2024)
• Net profit margin (quarter ending 30 Jun 2025): -138.74%
• Basic loss per share (H1 2025): CNY 0.10 to CNY 0.14
• EBITDA (quarter ending 30 Jun 2025): -CNY 159.91 million (down 607.71% YoY)
• Effective tax rate (quarter ending 30 Jun 2025): 22.88%
• Consecutive quarters with net losses: 10
• Recent sharp fall in net profit: -3,455.47%

Daan Gene Co., Ltd. (002030.SZ) - Debt vs. Equity Structure

Daan Gene's balance-sheet posture as of June 30, 2025, shows a capital structure heavily weighted toward equity with conservative leverage and comfortable liquidity.

• Total assets: CNY 9.12 billion
• Total liabilities: CNY 1.16 billion
• Total equity: CNY 7.95 billion
• Debt-to-equity ratio: ~0.146
• Cash & short-term investments: CNY 1.30 billion
• Net cash position: CNY 759.67 million (CNY 0.54 per share)
• Market capitalization (Dec 15, 2025): CNY 8.59 billion

Key implications for investors:

• Low leverage (0.146) reduces solvency risk and interest burden sensitivity.
• Net cash per share (CNY 0.54) offers a tangible liquidity buffer relative to market cap.
• Equity-dominant capitalization (87% of assets funded by equity) supports R&D and M&A optionality without high financing risk.

Further context on corporate history, ownership and business model can be found here: Daan Gene Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Daan Gene Co., Ltd. (002030.SZ) - Liquidity and Solvency

• Operating cash flow (Q2 2025): CNY 26.05 million, down 76.26% year-over-year.
• Free cash flow (Q2 2025): CNY 515.03 million, down 76.30% year-over-year.
• Current ratio: ~3.0 - ample short-term assets to cover liabilities.
• Quick ratio: ~2.5 - strong immediate liquidity excluding inventories.
• Net cash position: CNY 759.67 million (CNY 0.54 per share).
• Total assets: CNY 9.12 billion; total liabilities: CNY 1.16 billion - indicating low leverage.

• Implication: High current and quick ratios plus a net cash position and low leverage provide a strong buffer against short-term shocks, even as operating and free cash flow contracted sharply in the quarter.
• Consider monitoring operating cash trend over the next two quarters to assess whether the Q2 decline is temporary or indicative of weakening cash generation.

Daan Gene Co., Ltd. (002030.SZ) - Valuation Analysis

Daan Gene's current market metrics reflect a company priced at a premium to revenue while trading only modestly above its book value. Key headline figures (mid-December 2025) are summarized below and then examined for investor implications.

• The P/S of 11.22 signals investors are paying a strong premium for each yuan of revenue, common in high-growth or high-margin biopharma/testing firms where future earnings are priced in.
• A P/B of 1.12 implies limited downside protection from book value-market pricing is only slightly above net asset value, suggesting expectations are tied more to intangible growth prospects than to balance-sheet conservatism.

Comparing market capitalization (CNY 8.59b) to EV (CNY 8.67b) shows relatively low net debt or cash neutrality; the modest difference (EV ≈ market cap + net debt) implies the company's capital structure does not materially inflate enterprise valuation.

• Shares outstanding (1.40b) × share price (CNY 6.08) reconciles to the reported market cap (~CNY 8.51-8.59b depending on intra-day price variation), consistent with cited dates.
• With P/E not applicable due to losses, traditional earnings-based valuation is unavailable; investors must rely on revenue multiples, cash-flow projections, or comparator multiples within diagnostics/biotech sectors.

Practical considerations for investors:

• High P/S demands robust revenue growth or margin expansion to justify valuation-monitor quarterly revenue trends, gross margins, and EBITDA trajectory.
• P/B near 1 suggests limited asset-backed upside, so upside is linked to operational execution, product adoption, or margin improvement rather than asset revaluation.
• Given negative earnings, focus on cash runway, burn rate, and capital-raising history to assess dilution risk and sustainability.

For corporate context and strategic orientation that could affect valuation multiples, see: Mission Statement, Vision, & Core Values (2026) of Daan Gene Co., Ltd.

Daan Gene Co., Ltd. (002030.SZ) Risk Factors

• Net loss pressure: reported a net loss of CNY 925.17 million in 2024, following ten consecutive quarters of net losses, signaling persistent profitability challenges.
• Revenue concentration: the Biological Products sector accounts for 96.20% of total revenue, concentrating operational and market risk in a single segment.
• Declining sales and production: material decreases in sales volumes and production in Biological Products have directly reduced top-line and utilization rates.
• Demand and pricing exposure: sensitivity to industry demand fluctuations and pricing adjustments can rapidly depress revenue and gross margins.
• Valuation signals: a high price-to-sales (P/S) ratio of 11.22 may indicate market expectations that are difficult to meet given current earnings trends.
• Balance-sheet valuation: a price-to-book (P/B) ratio of 1.12 shows the market values the firm only slightly above its book equity, limiting downside cushion if asset impairments occur.

• Operational implications: sustained losses and declining production can trigger liquidity strain, potential asset write-downs, tighter credit terms, and investor dilution if equity financing is pursued.
• Market/strategic implications: heavy reliance on Biological Products requires either diversification or clear pathway to restoring volume and margin; otherwise, market expectations reflected in the P/S may be unrealistic.
• Event risks to monitor:
  • Further declines in product demand or regulatory changes affecting production.
  • Pricing competition or reimbursement pressure reducing realized selling prices.
  • Cash burn rate and access to financing amid consecutive losses.

Daan Gene Co., Ltd. (002030.SZ) - Growth Opportunities

• IVD application focus: continued investments in platforms and consumables for nucleic acid testing and immunodiagnostics to leverage steady post-pandemic demand.
• Mid-to-high-end innovation: allocation of R&D toward automated analyzers, next‑generation sequencing (NGS) support reagents, and higher‑throughput systems.
• Policy and market drivers: favorable health policy and reimbursement trends in China that prioritize domestic IVD capabilities and local supply chains.
• Reagent development: emphasis on modern biomedical engineering to create stable, shelf‑friendly diagnostic reagents for decentralized testing.
• Product expansion targets: infectious disease panels, oncology companion diagnostics, and expanded genetic testing menus.
• Go‑to‑market: focused marketing and distribution to hospitals, CDCs, third‑party testing labs and community health centers demanding quick turnaround.

• Where to invest R&D: prioritize platform modularity (multi‑pathogen panels), automation (to serve hospital labs), and expanding NGS reagent suites for oncology/genetic testing.
• Commercial expansion: strengthen distributor networks in lower‑tier cities and increase direct sales to Class III hospitals and public health labs.
• Policy alignment: pursue product registration and reimbursement approvals that unlock wider adoption in public health procurement.